JP2017500584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500584A5 JP2017500584A5 JP2016549205A JP2016549205A JP2017500584A5 JP 2017500584 A5 JP2017500584 A5 JP 2017500584A5 JP 2016549205 A JP2016549205 A JP 2016549205A JP 2016549205 A JP2016549205 A JP 2016549205A JP 2017500584 A5 JP2017500584 A5 JP 2017500584A5
- Authority
- JP
- Japan
- Prior art keywords
- assay
- biological sample
- hmwk
- autoimmune disease
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 21
- 102100011311 KNG1 Human genes 0.000 claims 21
- 239000012472 biological sample Substances 0.000 claims 20
- 206010003816 Autoimmune disease Diseases 0.000 claims 16
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 15
- 238000004166 bioassay Methods 0.000 claims 12
- 239000000523 sample Substances 0.000 claims 8
- 238000002965 ELISA Methods 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 206010011401 Crohn's disease Diseases 0.000 claims 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 201000006704 ulcerative colitis Diseases 0.000 claims 4
- 210000002381 Plasma Anatomy 0.000 claims 3
- 102000003827 Plasma kallikrein Human genes 0.000 claims 3
- 108090000113 Plasma kallikrein Proteins 0.000 claims 3
- 210000002966 Serum Anatomy 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 claims 3
- 238000003119 immunoblot Methods 0.000 claims 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 3
- 238000001262 western blot Methods 0.000 claims 3
- 230000001225 therapeutic Effects 0.000 claims 2
- 230000002250 progressing Effects 0.000 claims 1
Claims (26)
- 対象において自己免疫疾患を検出する方法であって、前記方法が、
自己免疫疾患を有することが疑われる対象の生物学的試料を提供することと、
前記生物学的試料中の切断型高分子量キニノーゲン(HMWK)の濃度を測定することと、
を含み、
前記生物学的試料中の切断型HMWKの、対照の試料と比較して上昇した濃度が、対象が自己免疫疾患を有しているかまたは自己免疫疾患の危険性があることを示す、
方法。 - 前記自己免疫疾患が、関節リウマチ、クローン病、もしくは潰瘍性大腸炎である、請求項1に記載の方法。
- 前記生物学的試料が血清試料もしくは血漿試料である、請求項1もしくは2に記載の方法。
- 前記生物学的試料が、その採取後に前記生物学的試料へと添加される一つもしくはそれ以上のプロテアーゼ阻害剤を含む、請求項1〜3のいずれか1項に記載の方法。
- 切断型HMWKの濃度が、切断型HMWKに特異的な結合剤を含むアッセイによって測定される、請求項1〜4のいずれか1項に記載の方法。
- 前記結合剤が抗体である、請求項5に記載の方法。
- 前記アッセイが、酵素結合免疫吸着測定法(ELISA)もしくはイムノブロットアッセイである、請求項4〜6のいずれか1項に記載の方法。
- 前記アッセイがLiCor検出を含むウェスタンブロットアッセイである、請求項4〜7のいずれか1項に記載の方法。
- 対象における自己免疫疾患の進行を監視する方法であって、前記方法が、
第一の時点において、自己免疫疾患を有することが疑われる対象の第一の生物学的試料を提供することと、
前記第一の生物学的試料中の切断型高分子量キニノーゲン(HMWK)の第一の濃度を測定することと、
前記第一の時点に続く第二の時点における前記対象の第二の生物学的試料を提供することと、
前記第二の生物学的試料中の切断型HMWKの第二の濃度を測定することと、
前記第一および第二の生物学的試料中の切断型HMWKの濃度変化に基づいて対象における自己免疫疾患の進行を判定することと、
を含み、
切断型HMWKの第二の濃度が切断型HMWKの第一の濃度よりも高いことが、自己免疫疾患が対象において進行していること、または対象が自己免疫疾患を発症したこともしくは自己免疫疾患を発症する危険性があることを示す、
方法。 - 前記自己免疫疾患が、関節リウマチ、クローン病、もしくは潰瘍性大腸炎である、請求項9に記載の方法。
- 前記第一および第二の生物学的試料が血清試料もしくは血漿試料である、請求項9もしくは10に記載の方法。
- 前記第一の生物学的試料、前記第二の生物学的試料またはその両方が、その採取後に前記生物学的試料に添加される一つもしくはそれ以上のプロテアーゼ阻害剤を含む、請求項9〜11のいずれか1項に記載の方法。
- 切断型HMWKの前記第一もしくは第二の濃度が、切断型HMWKに特異的な結合剤を含むアッセイによって測定される、請求項9〜12のいずれか1項に記載の方法。
- 前記結合剤が抗体である、請求項13に記載の方法。
- 前記アッセイが、酵素結合免疫吸着測定法(ELISA)もしくはイムノブロットアッセイである、請求項13もしくは14に記載の方法。
- 前記アッセイがLiCor検出を含むウェスタンブロットアッセイである、請求項13〜15のいずれか1項に記載の方法。
- 患者における自己免疫疾患の治療効果を判定する方法であって、前記方法が、
治療の過程において自己免疫疾患の治療を施される患者の複数の生物学的試料を提供することと、
前記複数の生物学的試料中の高分子量キニノーゲン(HMWK)の濃度を測定することと、
治療の過程における、切断型HMWKの濃度の変化に基づいて、前記患者における治療効果を判定することと、
を含み、
治療の過程において切断型HMWKの濃度が減少するのであれば、それは、患者において治療が有効であることを示す、
方法。 - 前記自己免疫疾患が、関節リウマチ、クローン病、もしくは潰瘍性大腸炎である、請求項17に記載の方法。
- 前記治療が少なくとも一つの血漿カリクレイン阻害剤を含む、請求項17もしくは18に記載の方法。
- 前記複数の生物学的試料の少なくとも一つが血清試料もしくは血漿試料である、請求項17〜19のいずれか1項に記載の方法。
- 前記複数の生物学的試料の少なくとも一つが、その回収後に前記試料へと添加される一つもしくはそれ以上のプロテアーゼ阻害剤を含む、請求項17〜19のいずれか1項に記載の方法。
- 前記複数の生物学的試料中の切断型HMWKの濃度が、切断型HMWKに特異的な結合剤を含むアッセイによって測定される、請求項17〜21のいずれか1項に記載の方法。
- 前記結合剤が抗体である、請求項22に記載の方法。
- 前記アッセイが、酵素結合免疫吸着測定法(ELISA)もしくはイムノブロットアッセイである、請求項22もしくは23に記載の方法。
- 前記アッセイがLiCor検出を含むウェスタンブロットアッセイである、請求項22〜24のいずれか1項に記載の方法。
- 対象における自己免疫疾患の治療における使用のための血漿カリクレイン(pKal)阻害剤であって、
前記対象は、健康対照と比較して切断型高分子量キニノーゲン(HMWK)の濃度が上昇しており、
前記自己免疫疾患は、関節リウマチ、クローン病、もしくは潰瘍性大腸炎であり、
任意選択で前記pKal阻害剤は、pKalに特異的な抗体であってもよい、
血漿カリクレイン(pKal)阻害剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361893542P | 2013-10-21 | 2013-10-21 | |
US61/893,542 | 2013-10-21 | ||
PCT/US2014/061242 WO2015061182A1 (en) | 2013-10-21 | 2014-10-17 | Diagnosis and treatment of autoimmune diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020018129A Division JP7157089B2 (ja) | 2013-10-21 | 2020-02-05 | 自己免疫疾患の診断と治療 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017500584A JP2017500584A (ja) | 2017-01-05 |
JP2017500584A5 true JP2017500584A5 (ja) | 2017-11-30 |
JP6657098B2 JP6657098B2 (ja) | 2020-03-04 |
Family
ID=52993412
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016549205A Active JP6657098B2 (ja) | 2013-10-21 | 2014-10-17 | 自己免疫疾患の診断と治療 |
JP2020018129A Active JP7157089B2 (ja) | 2013-10-21 | 2020-02-05 | 自己免疫疾患の診断と治療 |
JP2022161469A Pending JP2022191343A (ja) | 2013-10-21 | 2022-10-06 | 自己免疫疾患の診断と治療 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020018129A Active JP7157089B2 (ja) | 2013-10-21 | 2020-02-05 | 自己免疫疾患の診断と治療 |
JP2022161469A Pending JP2022191343A (ja) | 2013-10-21 | 2022-10-06 | 自己免疫疾患の診断と治療 |
Country Status (14)
Country | Link |
---|---|
US (3) | US10101344B2 (ja) |
EP (2) | EP3913364A1 (ja) |
JP (3) | JP6657098B2 (ja) |
KR (2) | KR102485948B1 (ja) |
CN (2) | CN105874332B (ja) |
AU (3) | AU2014340449B2 (ja) |
BR (1) | BR112016008975B1 (ja) |
CA (1) | CA2927695C (ja) |
DK (1) | DK3060908T3 (ja) |
ES (1) | ES2873204T3 (ja) |
IL (4) | IL293948A (ja) |
PL (1) | PL3060908T3 (ja) |
PT (1) | PT3060908T (ja) |
WO (1) | WO2015061182A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2897336C (en) * | 2013-01-20 | 2023-10-17 | Dyax Corp. | Evaluation and treatment of pkal-mediated disorders |
CN105873951A (zh) | 2013-10-21 | 2016-08-17 | 戴埃克斯有限公司 | 用于确定血浆激肽释放酶系统生物标记的试验 |
CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
PL3365685T3 (pl) | 2015-10-19 | 2021-08-02 | Dyax Corp. | Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu |
AU2017325983B2 (en) | 2016-09-16 | 2023-12-07 | Takeda Pharmaceutical Company Limited | Protein biomarkers for diseases associated with the contact activation system |
KR200490846Y1 (ko) | 2019-04-09 | 2020-01-13 | 이대호 | 각도조절 브라켓 |
KR20230050770A (ko) | 2021-10-08 | 2023-04-17 | 김경민 | 발로 열 수 있는 반려동물 울타리 |
WO2024003617A2 (en) * | 2022-06-30 | 2024-01-04 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
JPS63185398A (ja) | 1986-09-10 | 1988-07-30 | Nippon Zoki Pharmaceut Co Ltd | 生理活性物質測定法 |
US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
US5025796A (en) * | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
AU2548992A (en) | 1991-08-13 | 1993-03-16 | Temple University - Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US5795865A (en) | 1994-01-11 | 1998-08-18 | Dyax Corp. | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
EP0852004B1 (en) | 1995-10-11 | 2011-01-19 | Luminex Corporation | Multiplexed analysis of clinical specimens |
US6242210B1 (en) | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
JP4106888B2 (ja) | 2001-09-19 | 2008-06-25 | カシオ計算機株式会社 | 液晶表示装置および携帯端末装置 |
US8148171B2 (en) | 2001-10-09 | 2012-04-03 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
DK1531791T3 (da) | 2002-06-07 | 2010-11-01 | Dyax Corp | Forebyggelse og begrænsning af iskæmi |
WO2004001065A2 (en) | 2002-06-24 | 2003-12-31 | Cornell Research Foundation, Inc. | Exhaustive selection or rna aptamers against complex targets |
US20070003552A1 (en) | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
WO2004039487A1 (en) | 2002-11-01 | 2004-05-13 | Mcmaster University | Multicomponent protein microarrays |
WO2005024042A2 (en) | 2003-09-04 | 2005-03-17 | The Regents Of The University Of California | Aptamers and methods for their in vitro selection and uses thereof |
EP1700912B1 (en) | 2003-11-22 | 2014-10-29 | Techno Medica Co., Ltd. | Method of detecting target molecule by using aptamer |
EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
AU2005293752A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
EP1888640B1 (en) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Improved nanobodies against tumor necrosis factor-alpha |
CA2635589C (en) * | 2005-12-29 | 2017-01-17 | Dyax Corp. | Protease inhibition |
CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
WO2008064336A2 (en) * | 2006-11-22 | 2008-05-29 | Inivitrogen Corporation | Autoimmune disease biomarkers |
WO2008100791A1 (en) | 2007-02-16 | 2008-08-21 | Rules-Based Medicine, Inc. | Methods and kits for the diagnosis of sickle cell |
CA2696208A1 (en) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
EP2215256A1 (en) | 2007-10-22 | 2010-08-11 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
AU2009269257A1 (en) * | 2008-07-07 | 2010-01-14 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for detection of fibromyalgia |
JP2012507723A (ja) | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
WO2010065656A1 (en) | 2008-12-02 | 2010-06-10 | Joslin Diabetes Center | Method for reducing blood pressure using inhibitors of plasma kallikrein |
WO2010080833A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
KR101077275B1 (ko) * | 2009-05-07 | 2011-10-27 | 한국기초과학지원연구원 | 당단백질의 당쇄화를 이용한 암 진단 방법 |
JP5299179B2 (ja) | 2009-09-02 | 2013-09-25 | 株式会社リコー | 画像形成装置 |
US9206123B2 (en) * | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
US8609866B2 (en) | 2009-12-18 | 2013-12-17 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
RS57870B1 (sr) | 2010-01-06 | 2018-12-31 | Dyax Corp | Proteini koji vezuju kalikrein plazme |
WO2012009447A2 (en) * | 2010-07-13 | 2012-01-19 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
KR102107695B1 (ko) * | 2011-01-06 | 2020-05-07 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
US9187749B2 (en) * | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
EP3320922A1 (en) | 2011-06-10 | 2018-05-16 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
CA2897336C (en) | 2013-01-20 | 2023-10-17 | Dyax Corp. | Evaluation and treatment of pkal-mediated disorders |
CN105873951A (zh) | 2013-10-21 | 2016-08-17 | 戴埃克斯有限公司 | 用于确定血浆激肽释放酶系统生物标记的试验 |
CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
PL3365685T3 (pl) | 2015-10-19 | 2021-08-02 | Dyax Corp. | Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu |
WO2021154992A1 (en) * | 2020-01-28 | 2021-08-05 | Orgenesis Inc. | Process and system for acellular therapy |
-
2014
- 2014-10-17 CA CA2927695A patent/CA2927695C/en active Active
- 2014-10-17 PL PL14855002T patent/PL3060908T3/pl unknown
- 2014-10-17 CN CN201480069823.8A patent/CN105874332B/zh active Active
- 2014-10-17 JP JP2016549205A patent/JP6657098B2/ja active Active
- 2014-10-17 AU AU2014340449A patent/AU2014340449B2/en active Active
- 2014-10-17 EP EP21158440.4A patent/EP3913364A1/en active Pending
- 2014-10-17 BR BR112016008975-8A patent/BR112016008975B1/pt active IP Right Grant
- 2014-10-17 IL IL293948A patent/IL293948A/en unknown
- 2014-10-17 CN CN201910994046.2A patent/CN110658337B/zh active Active
- 2014-10-17 US US15/030,790 patent/US10101344B2/en active Active
- 2014-10-17 KR KR1020217026950A patent/KR102485948B1/ko active IP Right Grant
- 2014-10-17 PT PT148550023T patent/PT3060908T/pt unknown
- 2014-10-17 WO PCT/US2014/061242 patent/WO2015061182A1/en active Application Filing
- 2014-10-17 DK DK14855002.3T patent/DK3060908T3/da active
- 2014-10-17 EP EP14855002.3A patent/EP3060908B1/en active Active
- 2014-10-17 IL IL284969A patent/IL284969B/en unknown
- 2014-10-17 KR KR1020167013312A patent/KR102295623B1/ko active IP Right Grant
- 2014-10-17 ES ES14855002T patent/ES2873204T3/es active Active
-
2016
- 2016-04-19 IL IL245206A patent/IL245206B/en active IP Right Grant
-
2018
- 2018-09-14 US US16/131,781 patent/US10648990B2/en active Active
-
2020
- 2020-01-21 AU AU2020200423A patent/AU2020200423B2/en active Active
- 2020-02-05 JP JP2020018129A patent/JP7157089B2/ja active Active
- 2020-04-15 US US16/849,492 patent/US20200371120A1/en active Pending
- 2020-06-14 IL IL275368A patent/IL275368B/en unknown
-
2022
- 2022-06-29 AU AU2022204649A patent/AU2022204649A1/en active Pending
- 2022-10-06 JP JP2022161469A patent/JP2022191343A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017500584A5 (ja) | ||
Paramel Varghese et al. | NLRP 3 inflammasome expression and activation in human atherosclerosis | |
JP2016536012A5 (ja) | ||
JP2017524130A5 (ja) | ||
Stevenson et al. | α2-Macroglobulin can crosslink multiple Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) molecules and may facilitate adhesion of parasitized erythrocytes | |
CY1121872T1 (el) | Αξιολογηση, δοκιμασιες και θεραπεια των pkal-μεσολαβουμενων διαταραχων | |
Erickson et al. | Serum amyloid A: an ozone-induced circulating factor with potentially important functions in the lung-brain axis | |
JP2011177182A5 (ja) | ||
JP2010516678A5 (ja) | ||
JP2017505897A5 (ja) | ||
MA34263B1 (fr) | Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs) | |
Louis et al. | Extra-pulmonary complications in SARS-CoV-2 infection: a comprehensive multi organ-system review | |
WO2012017466A8 (en) | Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof | |
JP2006311860A5 (ja) | ||
WO2013009703A3 (en) | Antibodies, kit and method for detecting amyloid beta oligomers | |
JP2020091296A5 (ja) | ||
Kofla-Dłubacz et al. | Metalloproteinase-3 and-9 as novel markers in the evaluation of ulcerative colitis activity in children. | |
Tomerak et al. | Systemic inflammation in COVID‐19 patients may induce various types of venous and arterial thrombosis: a systematic review | |
Jia et al. | Rho kinase mediates Porphyromonas gingivalis outer membrane vesicle-induced suppression of endothelial nitric oxide synthase through ERK1/2 and p38 MAPK | |
Beltrán-Camacho et al. | The serum of COVID-19 asymptomatic patients up-regulates proteins related to endothelial dysfunction and viral response in circulating angiogenic cells ex-vivo | |
Ge et al. | Differential occurrence of lysine 2-hydroxyisobutyrylation in psoriasis skin lesions | |
Teran et al. | Respiratory proteomics: from descriptive studies to personalized medicine | |
Zeng et al. | Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis | |
Rottenstreich et al. | Assessment of the procoagulant potential after laparoscopic sleeve gastrectomy: a potential role for extended thromboprophylaxis | |
Vitko et al. | Characterizing patients with recurrent urinary tract infections in vesicoureteral reflux: a pilot study of the urinary proteome |